| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NurExone Biologic Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.60 |
| 52 Week High | CA$1.19 |
| 52 Week Low | CA$0.18 |
| Beta | 0 |
| 1 Month Change | -23.08% |
| 3 Month Change | 96.72% |
| 1 Year Change | 114.29% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -24.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| NRX | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -4.8% | 26.2% | -1.1% |
| 1Y | 114.3% | 84.7% | 4.9% |
Return vs Industry: NRX exceeded the Canadian Pharmaceuticals industry which returned 84.7% over the past year.
Return vs Market: NRX exceeded the Canadian Market which returned 4.9% over the past year.
Price Volatility
| NRX volatility | |
|---|---|
| NRX Average Weekly Movement | 46.0% |
| Pharmaceuticals Industry Average Movement | 15.1% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: NRX's share price has been volatile over the past 3 months.
Volatility Over Time: NRX's weekly volatility has increased from 32% to 46% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 12 | Lior Shaltiel | nurexone.com |
NurExone Biologic Inc., a pharmaceutical technology company. It engages in the development of an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.
NurExone Biologic Inc. Fundamentals Summary
| NRX fundamental statistics | |
|---|---|
| Market cap | CA$38.17m |
| Earnings (TTM) | -CA$5.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.9x
P/E RatioIs NRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.54m |
| Gross Profit | -US$1.54m |
| Other Expenses | US$2.10m |
| Earnings | -US$3.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.055 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 633.3% |
How did NRX perform over the long term?
See historical performance and comparison